Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) executives will speak at five investor conferences during November and December 2026. Appearances include Wolfe Research on November 10, UBS and Jefferies on November 17, Citi on December 1 and Evercore on December 2. Live webcasts will be available on the company’s investor relations website, with replays available for at least 30 days after each presentation.
Gilead Sciences (Nasdaq: GILD) reported third-quarter 2026 product sales of $8.3 billion, up 13% from the same period in 2025. Sales excluding Veklury rose 16% to $8.2 billion, while HIV sales increased 18% to $6.2 billion. Diluted earnings per share fell to $1.94 from $2.43, despite higher product gross margin.
Gilead raised its 2026 product-sales outlook to $31.0 billion–$31.3 billion from $30.1 billion–$30.4 billion, but widened its expected diluted loss per share to $4.05–$4.40 from $3.40–$3.75. Guidance includes approximately $9.88 per share from acquisition-related research charges, net of the Lakefront collaboration and related taxes. Cash, cash equivalents and marketable debt securities fell to $6.4 billion from $10.6 billion at year-end 2025. Updates included FDA approval of HIV treatment Bixlenvo and European authorization of Trodelvy with Keytruda for specified breast cancer patients.
Gilead Sciences (GILD) agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program for $1.275 billion in upfront cash.
The acquisition includes worldwide rights to lead asset HCXT-2001, currently in Phase 1 clinical trials. The oral peptide targets the IL-23 receptor, a target involved in immune-mediated inflammatory diseases. Gilead sees potential for the asset as a daily oral treatment for inflammatory bowel disease, alone or combined with other programs, including emvistegrast.
The upfront payment is due at closing and subject to customary adjustments. Gilead expects closing in the fourth quarter of 2026, subject to customary conditions, and an approximately $0.79 to $0.83 reduction in GAAP and non-GAAP earnings per share that quarter. HCXT-2001’s safety and efficacy have not been established, and it has no regulatory approval.
Gilead Sciences (GILD) will present rare liver disease research at The Liver Meeting in Denver, November 5–9, 2026. Its program includes 21 accepted abstracts, with late-breaking Phase 3 IDEAL results evaluating Livdelzi’s effect on normalization of alkaline phosphatase, a marker of disease activity, in primary biliary cholangitis.
IDEAL studied adults with lower enzyme elevations who were taking or could not tolerate ursodeoxycholic acid. Other presentations cover seladelpar safety and efficacy through five years and fatigue. Hepcludex research includes 96-week combined virologic and biochemical response findings and a 48-week analysis of elevated pressure in the liver’s portal circulation in chronic hepatitis delta.
Gilead Sciences (GILD) will present HIV and antiviral research at IDWeek 2026, taking place October 21–24 in Washington, D.C.
The 28 presentations, including two oral presentations, will cover HIV treatment, prevention and emerging antiviral research. Phase 3 ARTISTRY analyses will examine Bixlenvo outcomes in people with selected comorbidities or renal impairment. Other presentations will address rapid treatment restart with Biktarvy and early U.S. adoption of Yeztugo for HIV pre-exposure prophylaxis, or PrEP. Gilead will also present Phase 1b findings on the virologic efficacy, safety and tolerability of investigational GS-1179 for recurrent genital herpes.
Gilead Sciences (GILD) will release its third-quarter 2026 financial results and guidance after the market closes on October 29, 2026. Management will host a webcast at 4:30 p.m. Eastern Time that day to discuss the results and provide a business update. The webcast will be available in the Investors section of gilead.com and archived for one year.
Gilead Sciences (GILD) expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention as PrEP in 120 high-incidence, mainly low- and lower-middle-income countries.
The licenses with Dr. Reddy’s, Emcure, Eva Pharma, Ferozsons, Hetero and Mylan aim to support manufacturing readiness, technology transfer and supply planning during the ongoing Phase 3 PURPOSE 365 study. Gilead is also increasing the planned reach of its no-profit twice-yearly lenacapavir supply program by 50%, from 2 million to up to 3 million people through 2028, and has a new access agreement with the Pan American Health Organization for Latin America and the Caribbean.
Gilead Sciences (GILD) has signed a partnership with PAHO to expand access to twice-yearly lenacapavir PrEP across Latin America and the Caribbean.
The agreement uses PAHO’s Regional Revolving Funds to create a coordinated regional procurement and access pathway that supports country-led adoption and implementation of long-acting HIV prevention. It establishes a new access route for 14 PAHO Member States that are outside Gilead’s existing lenacapavir voluntary licensing agreements, complementing generic access pathways. The company has also increased its global no-profit lenacapavir supply program reach by 50%, from 2 million to up to 3 million people through 2028 via partnerships with PEPFAR and the Global Fund, and reports that lenacapavir is already available in 10 countries in sub-Saharan Africa.
Gilead Sciences (GILD) has opened a new 182,000-square-foot Research Center at its Foster City, California headquarters to expand work in oncology, inflammation and research data science.
The five-story facility is designed for approximately 325 employees, including 260 laboratory scientists, and uses flexible lab neighborhoods, collaboration spaces and shared technology platforms. It is one of three Foster City projects supporting Gilead’s previously announced $32 billion U.S. investment through 2030 and an estimated 3,000 domestic jobs. All-electric systems, energy-efficient design and water-saving landscaping are expected to support LEED Gold certification.
Gilead Sciences (Nasdaq:GILD) received U.S. FDA approval for Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for virologically suppressed adults with HIV, including those on complex multi-tablet regimens who cannot use existing STRs.
Bixlenvo combines guideline-recommended INSTI bictegravir with first-in-class capsid inhibitor lenacapavir, targeting multiple stages of the HIV life cycle. Approval is supported by Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed maintenance of virologic suppression at Week 48 and a generally well-tolerated safety profile, with headache, nausea and diarrhea as the most common adverse reactions.
The regimen requires a two-day oral initiation with Bixlenvo plus Sunlenca, followed by once-daily Bixlenvo. It is indicated as a complete regimen to replace current therapy in virologically suppressed adults with no known or suspected resistance to its components.